Market growth can largely be attributed to the rising demand for animal-derived food products, increasing incidence of zoonotic diseases, and the implementation of regulations to prevent the spread of animal diseases. Rising animal healthcare spending and the growing demand for pet insurance are further expected to drive the growth of this market. The untapped emerging markets such as China, India, and Brazil and growth in the overall companion animal population are also expected to offer significant growth opportunities to market players in the coming years
The global "Animal Antibiotics and Antimicrobials Market is projected
to reach USD 5.6 billion by 2026 from USD 4.7 billion in 2021, at a CAGR of
3.6% from 2021 to 2026.
Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=25161353
However, the limited number of new antibiotics, growing
resistance to antimicrobials and antibiotics, and increasing good husbandry and
hygiene practices are expected to hinder the growth of this market to a certain
extent.
The Tetracyclines segment accounted for the largest market share
in 2020.
Based on products, the global animal antimicrobials and
antibiotics market is segmented into tetracyclines, penicillins, sulfonamides,
macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins,
and other antimicrobial and antibiotic products. In 2020, the tetracyclines
segment accounted for 48.9% of the global animal antimicrobials and antibiotics
market. Tetracyclines exhibit advantages such as the highest potency against
pathogenic microorganisms, are well-absorbed, show low toxicity, and are
relatively inexpensive compared to other animal antimicrobial and antibiotic
products. These advantages contribute to the large share of this product
segment. The fluoroquinolones segment is expected to grow at the highest CAGR
of 8.0% during the forecast period. Advantages such as higher efficacy at low
concentrations, quick penetration through tissues, and the availability of
variations in the route of administration result in the higher adoption of
fluoroquinolones among end users.
The Premixes segment accounted for the largest market
share in 2020.
Based on the mode of delivery, the global animal antimicrobials
and antibiotics market is segmented into premixes, oral powders, oral
solutions, injections, and other modes of delivery. In 2020, the premixes
segment accounted for the largest share of 46.3% of the global animal
antimicrobials and antibiotics market. The large share of this segment can be
attributed to the advantages of premixes, such as simplified mode of
administration and lower instability and hygroscopicity of formulations. The
injections segment is expected to witness the highest CAGR of 4.9% during the
forecast period. Advantages such as immediate delivery of drugs and rapid onset
of drug effects are expected to drive growth in this market.
The food producing animal segment accounted for the
largest market share in 2020.
Based on animal type, the global animal antimicrobials and
antibiotics market is categorized into food-producing animals and companion
animals. In 2020, the food-producing animals segment accounted for the largest
share of around 73.4%. This segment is also expected to register the highest
CAGR of 3.9% during the forecast period. The large share of this segment is
mainly due to the rising demand for animal-derived food products, increase in
animal healthcare expenditure, and greater concerns about zoonotic diseases.
North America was the largest regional market for animal
antibiotics and antimicrobials market in 2020
The animal antimicrobials and antibiotics market is segmented
into five major regions: North America, Europe, Asia Pacific, Latin America,
and the Middle East & Africa. In 2020, North America accounted for the
largest share of 30.3% of the global animal antimicrobials and antibiotics
market.
Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=25161353
Some of the prominent players in the animal antimicrobials and
antibiotics market are Boehringer Ingelheim (Germany), Zoetis Inc. (US), Elanco
Animal Health (US), Merck & Co. Inc (US), Phibro Animal Health (US), Virbac
(France), Vetoquinol S.A. (France), Ceva Santé Animale (France), Dechra
Pharmaceuticals Plc (UK), Kyoritsu Seiyaku (Japan), Tianjin Ringpu (China),
HIPRA (Spain), Zydus Animal Health (US), China Animal Husbandry (China), and
Inovet (Belgium).
No comments:
Post a Comment